ReviewCurrent diabetes reports2006
Lipids and diabetic nephropathy.
Review in Current diabetes reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 84 citations in OpenAlex.
- Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial.Diabetes care · 2010Trial
- Chaperone-mediated autophagy ameliorates hyperlipidemia-induced apoptosis in podocytes via attenuating lipid accumulation.Journal of molecular histology · 2026Article
- The relationship between serum lipid levels and diabetic nephropathy in patients with primary diabetes.BMC nephrology · 2025Article
- The role of advanced glycation end products between thyroid function and diabetic nephropathy and metabolic disorders.Scientific reports · 2025Article
- Roflumilast ameliorates diabetic nephropathy in rats through down-regulation of JAK/STAT signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Identification of Probucol as a candidate for combination therapy with Metformin for Type 2 diabetes.NPJ systems biology and applications · 2023Article
- TGF-Beta as a Master Regulator of Diabetic Nephropathy.International journal of molecular sciences · 2021Review
- Protective Effect of Hydroxysafflor Yellow A on Nephropathy by Attenuating Oxidative Stress and Inhibiting Apoptosis in Induced Type 2 Diabetes in Rat.Oxidative medicine and cellular longevity · 2020Article
- Nelumbo nucifera leaves extract attenuate the pathological progression of diabetic nephropathy in high-fat diet-fed and streptozotocin-induced diabetic rats.Journal of food and drug analysis · 2019Article
- Renoprotective effect of JinQi-JiangTang tablet on high-fat diet and low-dose streptozotocin-induced type 2 diabetic rats.RSC advances · 2018Article
- NaoXinTong Capsules inhibit the development of diabetic nephropathy in db/db mice.Scientific reports · 2018Article
- Crosstalk of Hyperglycemia and Dyslipidemia in Diabetic Kidney Disease.Kidney diseases (Basel, Switzerland) · 2017Review
- Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes.Experimental and therapeutic medicine · 2017Article
- Soy-based renoprotection.World journal of nephrology · 2016Review
- Cordyceps militaris Treatment Preserves Renal Function in Type 2 Diabetic Nephropathy Mice.PloS one · 2016Article
- Article
- Simvastatin ameliorates low-dose streptozotocin-induced type 2 diabetic nephropathy in an experimental rat model.International journal of clinical and experimental medicine · 2015Article
- Genetic associations in diabetic nephropathy.Clinical and experimental nephrology · 2014Review
- The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?Nature reviews. Nephrology · 2014Review
- Proanthocyanidin Attenuation of Oxidative Stress and NF- κ B Protects Apolipoprotein E-Deficient Mice against Diabetic Nephropathy.Evidence-based complementary and alternative medicine : eCAM · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although several factors may mediate the development and progression of diabetic nephropathy, hyperlipidemia is now considered an independent and major determinant of progression of renal disease in diabetes. The following discussion focuses on the experimental evidence that incriminates hyperlipidemia as a pathogenic factor for diabetic nephropathy and the potential mechanisms that may mediate renal injury from hyperlipidemia, as well as the clinical studies involving therapeutic interventions for hyperlipidemia and their impact on progression of diabetic renal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.